Polymer-drug conjugates for combination anticancer therapy: Investigating the mechanism of action

Journal of Medicinal Chemistry

Volumn 52, Issue 20, 2009, Pages 6499-6502

  Pasut, Gianfranco ^a   Greco, Francesca ^b   Mero, Anna ^a   Mendichi, Raniero ^c   Fante, Cristina ^b   Green, Rebecca J ^b   Veronese, Francesco M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF READING   (United Kingdom)

^c CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; MACROGOL; NITRIC OXIDE;

ANIMAL EXPERIMENT; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG ELIMINATION; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; LIGHT SCATTERING; MICELLE; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; EPIRUBICIN; HUMANS; LIPID METABOLISM; MICE; NITRIC OXIDE; POLYETHYLENE GLYCOLS; SOLUTIONS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 70350054843     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900804m     Document Type: Article

References (17)

1. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6, 688-701.
2. Pasut, G.; Veronese, F. M. Polymer-drug conjugation, recent achievements and general strategies. Prog. Polym. Sci. 2007, 32, 933-961.
3. Seymour, L. W.; Ferry, D. R.; Kerr, D. J; Rea, D.; Whitlock, M.; Poyner, R.; et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34, 1629-1636.
4. Singer, J. W. Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane. J. Controlled Release 2005, 109, 120-126. (Pubitemid 41737258)
5. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 2001, 41, 189-207.
6. Zhao,H.;Rubio, B.; Sapra, P.;Wu,D.;Reddy, P.; Sai, P.;Martinez, A.; Gao, Y.; Lozanguiez, Y.; Longley, C.; Greenberger, L. M.; Horak, I. D. Novel prodrugs of SN38 using multiarmpoly(ethylene glycol) linkers. Bioconjugate Chem. 2008, 19, 849-859.
7. Satchi-Fainaro, R.; Puder, M.; Davies, J. W.; Tran, H. T.; Sampson, D. A.; Greene, A. K.; Corfas, G.; Folkman, J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 2004, 10, 255-261.
8. Santucci, L.; Mencarelli, A.; Renga, B.; Pasut, G.; Veronese, F. M.; Zacheo, A.; Germani, A.; Fiorucci, S. Nitric oxide modulates proand anti-apoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. FASEB J. 2006, 20, 765-767. (Pubitemid 46671208)
9. Vicent, M. J.; Greco, F.; Nicholson, R. I.; Paul, A.; Griffiths, P. C.; Duncan, R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew. Chem., Int. Ed. 2005, 44, 4061-4066. (Pubitemid 40886448)
10. Plosker, G. L.; Faulds, D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993, 45, 788-856. (Pubitemid 23177452)
11. Ryberg, M.; Nielsen, D.; Skovsgaard, T.; Hansen, J.; Jensen, B. V.; Dombernowsky, P. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. J. Clin. Oncol. 1998, 16, 3502-3508.
12. Maejima, Y.; Adachi, S.; Morikawa, K.; Ito, H.; Isobe, M. Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J. Mol. Cell Cardiol. 2005, 38, 163-174.
13. Evig, C. B.; Kelley, E. E.; Weydert, C. J.; Chu, Y.; Buettner, G. R.; Burns, C. P. Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts. Nitric Oxide 2004, 10, 119-129.
14. Santucci, L.; Mencarelli, A.; Renga, B.; Ceccobelli, D.; Pasut, G.; Veronese, F. M.; Distrutti, E.; Fiorucci, S. Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anti-Cancer Drugs. 2007, 18, 1081-1091. (Pubitemid 47294902)
15. Pasut, G.; Scaramuzza, S.; Schiavon, O.; Mendichi, R.; Veronese, F. M. PEG-epirubicin conjugates with high loading. J. Bioact. Compat. Polym. 2005, 20, 213-230.
16. Schiavon, O.; Pasut, G.; Guiotto, A.; Moro, S.; Orsolini, P.; Veronese, F. M. PEG-Ara-C conjugates for controlled release. Eur. J. Med. Chem. 2004, 39, 123-133.
17. Veronese, F. M.; Schiavon, O.; Pasut, G.; Mendichi, R.; Andersson, L.; Tsirk, A.; Ford, J.; Wu, G.; Kneller, S.; Davis, J.; Duncan, R. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjugate Chem. 2005, 16, 775-784. (Pubitemid 41026163)